Trial
NCT03922477
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Atezolizumab
Why stopped
The Sponsor decided to discontinue the development of atezolizumab in combination with magrolimab in the AML indication.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-21